GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » Asset Turnover

Sinco Pharmaceutical Holdings (HKSE:06833) Asset Turnover : 0.82 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Sinco Pharmaceutical Holdings's Revenue for the six months ended in Dec. 2023 was HK$1,586 Mil. Sinco Pharmaceutical Holdings's Total Assets for the quarter that ended in Dec. 2023 was HK$1,932 Mil. Therefore, Sinco Pharmaceutical Holdings's Asset Turnover for the quarter that ended in Dec. 2023 was 0.82.

Asset Turnover is linked to ROE % through Du Pont Formula. Sinco Pharmaceutical Holdings's annualized ROE % for the quarter that ended in Dec. 2023 was 7.38%. It is also linked to ROA % through Du Pont Formula. Sinco Pharmaceutical Holdings's annualized ROA % for the quarter that ended in Dec. 2023 was 2.58%.


Sinco Pharmaceutical Holdings Asset Turnover Historical Data

The historical data trend for Sinco Pharmaceutical Holdings's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinco Pharmaceutical Holdings Asset Turnover Chart

Sinco Pharmaceutical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.62 2.02 1.66 1.64 1.52

Sinco Pharmaceutical Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 0.78 0.74 0.70 0.82

Competitive Comparison of Sinco Pharmaceutical Holdings's Asset Turnover

For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinco Pharmaceutical Holdings's Asset Turnover Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Sinco Pharmaceutical Holdings's Asset Turnover falls into.



Sinco Pharmaceutical Holdings Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Sinco Pharmaceutical Holdings's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=2778.267/( (1590.574+2067.984)/ 2 )
=2778.267/1829.279
=1.52

Sinco Pharmaceutical Holdings's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=1585.91/( (1795.829+2067.984)/ 2 )
=1585.91/1931.9065
=0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Sinco Pharmaceutical Holdings  (HKSE:06833) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Sinco Pharmaceutical Holdings's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=49.782/674.505
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(49.782 / 3171.82)*(3171.82 / 1931.9065)*(1931.9065/ 674.505)
=Net Margin %*Asset Turnover*Equity Multiplier
=1.57 %*1.6418*2.8642
=ROA %*Equity Multiplier
=2.58 %*2.8642
=7.38 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Sinco Pharmaceutical Holdings's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=49.782/1931.9065
=(Net Income / Revenue)*(Revenue / Total Assets)
=(49.782 / 3171.82)*(3171.82 / 1931.9065)
=Net Margin %*Asset Turnover
=1.57 %*1.6418
=2.58 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Sinco Pharmaceutical Holdings Asset Turnover Related Terms

Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinco Pharmaceutical Holdings (HKSE:06833) Business Description

Traded in Other Exchanges
N/A
Address
No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN
Sinco Pharmaceutical Holdings Ltd is an investment holding company engaged in the provision of comprehensive marketing, promotion, and channel management service for imported pharmaceutical products and medical devices in China. The company has three operating segments; the sale of imported pharmaceutical products segment, the research and manufacturing of aesthetic medicine segment, and the medical beauty services segment. Its product offering includes Human albumin solutions and Antibiotics like Axetine and Medocef.
Executives
Huang Zhijian 2305 Beneficiary of a trust
Fullwealth Holdings Limited 2201 Interest of corporation controlled by you
Risun Investments Limited 2101 Beneficial owner
Wickhams Cay Trust Company Limited 2301 Trustee
Huang Xiangbin 2307 Founder of a discretionary trust who can infl

Sinco Pharmaceutical Holdings (HKSE:06833) Headlines

No Headlines